Clinical Trial Update: A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of Somavaratan in Japanese children with growth hormone deficiency has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Somavaratan (somavaratan)

Snippet

Sponsor: Versartis Inc. | Conditions: Growth Hormone Deficiency | Phase 3 | Status: TERMINATED